Perioperative treatment for high-risk pancreatic cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of drugs (nimotuzumab, nab-paclitaxel, and gemcitabine) given before and after surgery for pancreatic cancer that is either removable or borderline removable but has high-risk features. The goal is to see if this approach improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with pancreatic ductal adenocarcinoma (a common type of pancreatic cancer).
- Your cancer is considered resectable or borderline resectable (removable with surgery) but has at least one high-risk feature, such as high CA19-9 levels, a tumor larger than 3 cm, significant weight loss, severe pain, or lymph node involvement.
- You are willing to provide samples for KRAS gene testing and other research.
- Your organ and bone marrow function are adequate (e.g., blood counts and liver/kidney tests within limits).
- You have not had previous treatment for pancreatic cancer.
- You do not have other serious illnesses or conditions that would make participation unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two treatments: a targeted antibody therapy called nimotuzumab with chemotherapy, followed by a procedure that uses electrical pulses to destroy tumor cells. It is for people with locally advanced pancreatic cancer that has not spread, and aims to see if this approach can help control the disease.
This trial tests combining nimotuzumab with chemotherapy (nab-paclitaxel and gemcitabine) after surgery to prevent pancreatic cancer from returning. It is for people whose tumors have a protein called EGFR, and whose cancer was removed with clear or close margins.
This trial tests adding nimotuzumab (a targeted therapy) to standard chemotherapy for people whose pancreatic cancer was completely removed with surgery. The goal is to see if this combination helps prevent the cancer from coming back.
This trial tests a combination of an immunotherapy drug (adebrelimab) with chemotherapy before surgery for pancreatic cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial tests a new targeted drug (HRS-4642) combined with another drug (Nimotuzumab) and two chemotherapy drugs for people with a specific type of pancreatic cancer that has a KRAS G12D mutation. The goal is to see if this combination can help make the tumor smaller and possibly removable by surgery.
This trial tests a new targeted drug (HRS-4642) combined with nimotuzumab and chemotherapy for people with advanced pancreatic cancer that has a specific gene change called KRAS G12D. It's for those who haven't had treatment for advanced disease yet.
Hear when a new Pancreatic Cancer, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.